Stendhal, a Mexican pharmaceutical company that offers innovative therapies to improve the quality of life of patients; With a presence in Mexico and Latin America, is pleased to announce a new collaboration with Adalvo, a global pharmaceutical company with a presence in more than 16 countries and one of the leading B2B pharmaceutical companies in Europe. This alliance will be for the production and distribution of a complex antibiotic product for the treatment of acute bacterial infections of the skin and skin structures (ABSSI by its name in English), which will be available in Mexico and Colombia.
The alliance between Stendhal and Adalvo will be in force for the next 10 years, which will make it possible to deliver a reliable antibiotic within the reach of the medical community and patients in Mexico and Latin America, with which different types of skin infections can be treated, in order to that positive results are achieved and in less time, particularly complicated cases, avoiding in many cases the need for patients to be hospitalized to receive their treatment. The distribution of this antibiotic will be available in Mexico from 2026.
The start of this alliance with Adalvo is a sign of the commitment that Stendhal has to find solutions to problems that affect human health, and will continue to strengthen its portfolio with the integration of more products for Mexico and the region.
Join the Team
We are open to professionals with a high level of initiative, with the capacity to transform uncertainty into opportunities.